Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

F

First Affiliated Hospital of Fujian Medical University

Other

0

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

0

Indications↗

Distinct diseases across all programs

49

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

68Ga-P16-093 PET Imaging in the Diagnostic Study of Newly Diagnosed, Untreated Prostate Cancer, With a Head-to-head Comparison to mpMRI

Active, not recruiting

First-in-Human Safety and Dosimetry Study of ¹⁷⁷Lu-FAPI in Patients With FAP-Positive Malignancies

Earlier

Feb 1, 2026TrialComparing Different Doses of Corticosteroids in Local Infiltration Analgesia (LIA) for Total Knee Arthroplasty

Dec 20, 2025TrialThe Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

Nov 13, 2025TrialRifampin-combined Antibiotic Therapy for Staphylococcal PJI

Jun 1, 2025TrialCombined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance

May 15, 2025TrialResearch on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer

Apr 22, 2025TrialProspective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

3 more events

Apr 1, 2025TrialSequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Mar 1, 2025TrialDosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73

Nov 1, 2024Trial68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)